CB-5083 is a potent and selective inhibitor of p97 (also known as VCP), a key ATPase involved in the ubiquitin-proteasome system. It disrupts protein homeostasis by blocking the degradation of ubiquitinated proteins, leading to endoplasmic reticulum stress and activation of the unfolded protein response. This mechanism makes CB-5083 a promising candidate in cancer therapy, particularly for tumors reliant on efficient protein clearance, such as multiple myeloma and certain solid tumors. In preclinical studies, CB-5083 has shown antitumor activity by inducing apoptosis in cancer cells. Its ability to target the p97 pathway offers a novel approach in oncology, especially for cancers resistant to proteasome inhibitors. Research continues to explore its efficacy and potential in combination therapies.